Business Wire

ADDING MULTIMEDIA FDA Approves JUVÉDERM VOLUMA™ XC

IRVINE, Calif.--(BUSINESS WIRE)--Allergan, Inc., (NYSE:AGN) today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market JUVÉDERM VOLUMA™ XC, the ...
Nasdaq

Allergan : FDA Oks Juvéderm VOLUMA XC For Mid-Face Injection Via Cannula

(RTTNews) - Allergan plc (AGN) said that it received U.S. Food and Drug Administration approval for the use of Juvéderm VOLUMA XC, a hyaluronic acid gel dermal filler, with a TSK STERiGLIDE cannula ...
Stockhouse

Allergan Receives FDA Approval of Juvéderm VOLUMA® XC For Mid-Face Injection Via Cannula

DUBLIN, Sept. 3, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) announced today it received U.S. Food and Drug Administration (FDA) approval for the use of Juvéderm VOLUMA ® XC, a hyaluronic acid gel ...
Monthly Prescribing Reference

FDA Approves Juvéderm Voluma XC to Improve Temple Hollowing

At 3 months, findings showed 80.4% of patients treated with Juvéderm Voluma XC achieved at least a 1-point improvement in moderate to severe temple hollowing. The Food and Drug Administration (FDA) ...
Medscape

FDA Approves New Indication for Dermal Filler

The Food and Drug Administration has approved the hyaluronic acid dermal filler Juvéderm Voluma XC for injection in the temple region to improve moderate to severe temple hallowing in individuals over ...